Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Synergetisch effect van radiotherapie + immuuntherapie bij NSCLC
mei 2021 | Immuuntherapie, Longoncologie, Radiotherapie